MCID: ALL010
MIFTS: 56

Allergic Contact Dermatitis

Categories: Immune diseases, Skin diseases

Aliases & Classifications for Allergic Contact Dermatitis

Summaries for Allergic Contact Dermatitis

PubMed Health : 63 About allergic contact dermatitis: A number of chemical or herbal substances can irritate the skin. Redness, burning or itching are normal skin reactions, for instance, to aggressive cleaning agents. Allergic contact dermatitis (sometimes simply called “contact allergies”) is different, though. Here the immune system overreacts to certain substances – sometimes to very small amounts – that normally wouldn’t cause a reaction. Common examples include certain metals, scents and latex rubber. Contact allergies can lead to severe skin reactions. Unlike with many other kinds of allergies, the reaction doesn’t occur immediately, but after one to three days. And contact allergies develop gradually over a long period of time, as a result of repeated contact with the substance that triggers them. Some people are then no longer able to carry on doing the same kind of work as before.

MalaCards based summary : Allergic Contact Dermatitis, also known as dermatitis, allergic contact, is related to palladium allergic contact dermatitis and nickel allergic contact dermatitis. An important gene associated with Allergic Contact Dermatitis is IL31 (Interleukin 31), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Hydrocortisone and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A contact dermititis that is an allergic skin reaction to foreign chemical or substances leading to red, itchy, weepy reaction where the skin has come into contact with a substance that the immune system recognizes as foreign.

KEGG : 37
Allergic contact dermatitis (ACD) is a T-cell mediated skin inflammation caused by repeated skin exposure to contact allergens. Although regarded as a dermatosis that is typically triggered by environmental factors, ACD may affect certain individuals more easily than others. A higher risk for polysensitization has been found for polymorphism in the TNFA (TNFA-308) and IL-16 (IL-16-295 C/C) genes.

Wikipedia : 75 Allergic contact dermatitis (ACD) is a form of contact dermatitis that is the manifestation of an... more...

Related Diseases for Allergic Contact Dermatitis

Diseases related to Allergic Contact Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 480)
# Related Disease Score Top Affiliating Genes
1 palladium allergic contact dermatitis 34.6 IL17A IL10 CCL17
2 nickel allergic contact dermatitis 34.3 IL5 IL4 IL10 IFNG
3 toxicodendron dermatitis 33.2 ICAM1 CXCL8
4 vasculitis 31.0 TNF SELE ICAM1
5 irritant dermatitis 31.0 TNF IL1B FLG
6 alopecia areata 31.0 TNF IFNG ICAM1
7 dermatitis 30.9 IL5 IL4 IL31 IL17A IFNG FLG
8 erythema multiforme 30.9 TNF IFNG ICAM1 CXCR3 CCL17
9 mycosis fungoides 30.8 IL5 CXCR3 CCL17
10 ige responsiveness, atopic 30.8 IL5 IL4 IL10 IFNG
11 leprosy 3 30.8 TNF IL10 IFNG
12 allergic hypersensitivity disease 30.7 IL5 IL4 IL10 IFNG CCL17
13 acute generalized exanthematous pustulosis 30.5 IL17A CXCL8
14 stevens-johnson syndrome/toxic epidermal necrolysis 30.5 IL5 IFNG CXCR3 CCL17
15 scabies 30.4 IL10 CXCL8
16 cutaneous lupus erythematosus 30.4 TNF SELE ICAM1 CXCR3
17 latex allergy 30.4 IL5 IL4 FLG
18 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.3 IL17A IL10 IFNG
19 hypereosinophilic syndrome 30.3 IL5 IL4 CCL17
20 severe acute respiratory syndrome 30.2 TNF IFNG CXCL8
21 rhinitis 30.2 IL5 IL4 ICAM1 CXCL8
22 folliculitis 30.1 IL5 IL4 IFNG
23 tetanus 30.1 IL5 IL4 IL10 IFNG
24 cutaneous t cell lymphoma 30.1 IL4 IFNG CCL17
25 pulpitis 29.9 TNF IL1B CXCL8
26 pertussis 29.7 TNF IL1B IL10
27 actinic prurigo 29.7 TNF SELE IL1B ICAM1
28 human immunodeficiency virus type 1 29.6 TNF IL10 IFNG CD4
29 lichen planus 29.5 TNF IL4 IFNG ICAM1 FLG CXCR3
30 conjunctivitis 29.4 IL5 IL4 IL33 IFNG ICAM1 CXCL8
31 esophagitis 29.4 IL5 IL1B CXCL8
32 sarcoidosis 1 29.3 TNF IL1B IFNG CXCR3 CCL17
33 sleep apnea 29.3 TNF IL1B ICAM1 CXCL8
34 crohn's colitis 29.2 TNF IL1B IFNG CXCL8
35 food allergy 29.1 IL5 IL4 IL10 IFNG FLG
36 respiratory allergy 29.1 IL5 IL4 IL33 IL17A IL10
37 allergic asthma 29.1 IL5 IL4 IL17A IL10 IFNG CCL17
38 allergic conjunctivitis 28.9 IL5 IL4 IL33 IFNG ICAM1 CXCL8
39 osteomyelitis 28.8 TNF IL1B IL10 IFNG CXCL8
40 acquired immunodeficiency syndrome 28.8 TNF IL1B IL10 IFNG CD4
41 allergic rhinitis 28.7 IL5 IL4 IL10 IFNG ICAM1 CXCL8
42 autoimmune disease 28.6 TNF IL4 IL1B IL17A IL10 IFNG
43 otitis media 28.6 TNF IL4 IL1B IL10 CXCL8
44 arthritis 28.3 TNF IL1B IL17A IL10 IFNG CXCL8
45 lung disease 27.9 TNF IL5 IL1B IL17A IL10 CXCR3
46 contact dermatitis 27.7 TNF SELE IL5 IL4 IL31 IL1B
47 dermatitis, atopic 27.5 TNF SELE IL5 IL4 IL31 IL17A
48 skin disease 27.5 TNF SELE IL5 IL4 IL31 IL17A
49 proteasome-associated autoinflammatory syndrome 1 26.9 TNF SELE IL5 IL4 IL1B IL17A
50 asthma 25.1 TNF SELE IL5 IL4 IL31 IL1B

Graphical network of the top 20 diseases related to Allergic Contact Dermatitis:



Diseases related to Allergic Contact Dermatitis

Symptoms & Phenotypes for Allergic Contact Dermatitis

GenomeRNAi Phenotypes related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 CXCL8 ICAM1 IL10 IL17A IL1B TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 CXCL8 ICAM1 IL10 IL17A IL1B TNF

MGI Mouse Phenotypes related to Allergic Contact Dermatitis:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 CCL17 CD4 CXCR3 ICAM1 IFNG IL10
2 cellular MP:0005384 10.22 CCL17 CD4 CXCR3 ICAM1 IFNG IL10
3 homeostasis/metabolism MP:0005376 10.18 CD4 CXCR3 ICAM1 IFNG IL10 IL17A
4 immune system MP:0005387 10.18 CCL17 CD4 CXCR3 ICAM1 IFNG IL10
5 growth/size/body region MP:0005378 10.16 CD4 ICAM1 IFNG IL10 IL17A IL1B
6 digestive/alimentary MP:0005381 10.15 CD4 ICAM1 IFNG IL10 IL17A IL33
7 endocrine/exocrine gland MP:0005379 10.08 CD4 ICAM1 IFNG IL10 IL17A IL33
8 mortality/aging MP:0010768 10 CD4 CXCR3 ICAM1 IFNG IL10 IL17A
9 craniofacial MP:0005382 9.99 IFNG IL10 IL17A IL1B IL4 TNF
10 integument MP:0010771 9.97 CD4 ICAM1 IFNG IL10 IL1B IL33
11 neoplasm MP:0002006 9.7 CXCR3 ICAM1 IFNG IL10 IL1B IL5
12 no phenotypic analysis MP:0003012 9.5 CD4 IFNG IL10 IL17A IL33 IL4
13 respiratory system MP:0005388 9.28 CXCR3 IFNG IL10 IL17A IL33 IL4

Drugs & Therapeutics for Allergic Contact Dermatitis

PubMed Health treatment related to Allergic Contact Dermatitis: 63

Allergic skin reactions are usually treated with steroid creams, ointments or solutions. But the main thing to do is avoid contact with the substance that triggers the reaction. Protective gloves and clothing can help here, for instance. A change of career may have to be considered if it isn’t possible to avoid contact with the substance in the workplace. If you are believed to have a work-related contact allergy, it’s a good idea to have your doctor inform your employer’s liability insurance. The insurance will cover certain costs, like the costs of protective measures, if the allergy is recognized as being work-related.

Drugs for Allergic Contact Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 99)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
2
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
3
Bronopol Approved Phase 4 52-51-7
4
Povidone Approved Phase 4 9003-39-8
5
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
6 Gold Sodium Thiosulfate Phase 4
7 Antidotes Phase 4
8 Antioxidants Phase 4
9 sodium thiosulfate Phase 4
10 Chelating Agents Phase 4
11 Antitubercular Agents Phase 4
12 Hydrocortisone-17-butyrate Phase 4
13 Hydrocortisone hemisuccinate Phase 4
14 Hydrocortisone 17-butyrate 21-propionate Phase 4
15 Immunologic Factors Phase 4
16 Immunosuppressive Agents Phase 4
17 Antibodies Phase 4
18 Antibodies, Monoclonal Phase 4
19 Immunoglobulins Phase 4
20 Analgesics Phase 4
21 Peripheral Nervous System Agents Phase 4
22 Analgesics, Non-Narcotic Phase 4
23 Anti-Inflammatory Agents, Non-Steroidal Phase 4
24 Anti-Bacterial Agents Phase 4
25 Anti-Inflammatory Agents Phase 4
26 Anti-Infective Agents Phase 4
27 Antirheumatic Agents Phase 4
28 Angiogenesis Inhibitors Phase 4
29 Angiogenesis Modulating Agents Phase 4
30
Petrolatum Approved, Investigational Phase 3 8009-03-8
31
Silver sulfadiazine Approved, Vet_approved Phase 3 22199-08-2 441244
32
Sulfadiazine Approved, Investigational, Vet_approved Phase 3 68-35-9 5215
33 Anti-Infective Agents, Local Phase 3
34 Dermatologic Agents Phase 3
35 Emollients Phase 3
36 Antiparasitic Agents Phase 3
37 Antiprotozoal Agents Phase 3
38 Parthenolide Approved, Investigational Phase 2 20554-84-1
39
Bacitracin Approved, Vet_approved Phase 2 1405-87-4 439542 10909430
40
Minoxidil Approved, Investigational Phase 2 38304-91-5 4201
41 Pharmaceutical Solutions Phase 1, Phase 2
42 Phosphodiesterase 4 Inhibitors Phase 2
43 Antihypertensive Agents Phase 2
44 Vasodilator Agents Phase 2
45
Denosumab Approved Phase 1 615258-40-7
46
Squaric acid dibutyl ester Investigational Phase 1 2892-62-8
47 Bone Density Conservation Agents Phase 1
48 Adjuvants, Immunologic Phase 1
49
Betamethasone Approved, Vet_approved 378-44-9 9782
50 Grape Approved

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Clinical Evaluation of T.R.U.E. Test Panel 3.2 in Children and Adolescents (PREA II) Unknown status NCT01797562 Phase 4 T.R.U.E. Test Panel 3.2
2 An Open Single Centre Evaluation of the Reactivity of the T.R.U.E. Test Quaternium-15 Patch and a Real Use Exposure in Subjects Known to Be Allergic to Quaternium-15 Unknown status NCT00311454 Phase 4 T.R.U.E.Test
3 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Trial to Assess the Safety and Efficacy of 0.1% Tacrolimus Ointment in the Treatment of Chronic Allergic Contact Dermatitis Completed NCT00667056 Phase 4 tacrolimus ointment;placebo ointment
4 Clinical Evaluation of TRUE Test Ethylenediamine Dihydrochloride Allergen: Bioequivalence of Vehicle Formulations Completed NCT01798589 Phase 4 Ethylenediamine dihydrochloride
5 Clinical Evaluation of T.R.U.E. TEST® Panel 1.1, 2.1 and 3.1: in Children and Adolescents Completed NCT00795951 Phase 4
6 The Effects of Dupilumab on Allergic Contact Dermatitis Not yet recruiting NCT03935971 Phase 4 Dupilumab
7 An Open-label, Single-Arm Pilot Study Investigating the Efficacy and Safety of Apremilast for the Treatment of Moderate to Severe Chronic Hand Dermatitis Not yet recruiting NCT03741933 Phase 4 Apremilast 30mg
8 Anti-IL-17 a New Treatment for Contact Dermatititis Unknown status NCT02778711 Phase 3 secukinumab
9 A Randomized Controlled Clinical Trial Comparing The Efficacy and Safety of Open Dressing With Petrolatum Jelly vs. Standard Gauze Dressing With Silver Sulfadiazine in the Treatment of Filipino Adults Aged 18-45 Years Old With Superficial Partial Thickness Burns Less Than or Equal to 10% Total Surface Area Who Are Seen at the Philippine General Hospital Burn Outpatient Clinic Completed NCT02109718 Phase 3 Open Dressings with Petrolatum Jelly;Silver Sulfadiazine Gauze Dressing Group
10 An Efficacy and Safety Pilot Study Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Treatment of AGA Unknown status NCT01650272 Phase 1, Phase 2 5% MInoxidil milky lotion;5% Minoxidil solution
11 A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of Three Weeks of Daily Dermal Application of MRX-6 (2% HyPE) on the Treatment of Mild to Moderate Contact Dermatitis of the Hand and Forearm Completed NCT00867607 Phase 1, Phase 2 MRX-6;Steroid
12 Clinical Evaluation of Bacitracin. A Phase II Dose-Response Study Completed NCT00132600 Phase 2 bacitracin (allergen)
13 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis Completed NCT00928447 Phase 2 rHuPH20;Placebo
14 Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate for ”TRUE Test® Panel 3” – a Phase II, Dose-Response Study. Completed NCT00133341 Phase 2 Goldnatriomthiosulphate, MDBGN, parthenolide
15 A Phase 2, Open-label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Contact or Atopic Dermatitis Completed NCT00931242 Phase 2 Apremilast
16 A Randomized, Double-Blind, Vehicle-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Adult Subjects With Moderate to Severe Chronic Allergic Contact Dermatitis Not yet recruiting NCT03680131 Phase 2 EB01 Cream Placebo;EB01 Cream 0.2%;EB01 Cream 1.0%;EB01 Cream 2.0%
17 Clinical Treatment of Alopecia Areata With Stem Cell Educator Therapy and Oral Minoxidil Not yet recruiting NCT04011748 Phase 2
18 A Proof-of-Principle Study Investigating the Effect of Single Doses of NI-0801 on Nickel Induced Contact Dermatitis Completed NCT01244607 Phase 1 Placebo;NI-0801
19 Placebo-Controlled, Randomized, Parallel Group, Multiple-Dose Study to Evaluate the Effects of CP-481,715 on Clinical Response and Cellular Infiltration Following Contact Allergen Challenge to the Skin of Nickel Allergic Subjects. Completed NCT00141180 Phase 1 CP-481,715
20 Effect of RANKL Inhibition on UV-induced Immunosuppression Completed NCT01978483 Phase 1 Denosumab;Diphenylcyclopropenone;Normal Saline
21 A Phase I Study of the Immune Response to Herpes Simplex Virus Type 1 (HSV-1) and General Immune Health in Subjects Infected With HSV-1 Completed NCT03661541 Phase 1 Squaric Acid Dibutyl Ester
22 Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation Unknown status NCT00445029
23 Nickel Desensitization Using Topical Therapy Unknown status NCT01413477 Calcipotriol, Betamethasone, Calcipotriol & Betamethasone
24 Evaluating Results of Regularly Applied Emollient - Spray in Atopic Dermatitis Therapy Unknown status NCT02763722
25 Hand Eczema Trial: A Randomised Clinical Trial of the Effect of Classification and Individual Counselling Among Health Care Workers With Hand Eczema Unknown status NCT01012453
26 Oral Human Administration of Red Grape Polyphenol in Nickel-mediated Allergic Contact Dermatitis: an in Vitro Study Completed NCT03902392
27 Low Dose Exposure to Oxidized R-limonene - A Double Blinded Vehicle Controlled Repeated Open Application Test (ROAT) Study Completed NCT03313232
28 Epidemiology and Co-Reactivity of Novel Surfactant Allergens Completed NCT02534441
29 Analysis of Immune Reactions Occurring Upon Administration of Patch Tests and Contact Dermatitis Affected Skin Completed NCT01546298
30 Evaluation of the Clinical Implication of Short Repeated Nickel Exposures Completed NCT03309215
31 Intervention Study to Evaluate the Importance of Information Given to Patients With Contact Allergy Completed NCT01953380
32 Human Repeated Insult Patch Test Completed NCT03474874
33 Skin Prick Test in Healthy Volunteers of Any Sex, to Investigate the Potential Allergy to NeoMatriXTM Wound Matrix Completed NCT03522675
34 Oral Metal Contact Allergy: A Cause of Oral Squamous Cell Carcinoma? Completed NCT00693550
35 A Study to Determine if Tetrix Cream Impedes the Resolution of Experimentally Induced Allergic Contact Dermatitis Completed NCT00643214
36 Medrol® In Contact Dermatitis: A Prospective Study To Assess The Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Subjects Completed NCT00929981 Tablet Methylprednisolone (4 or 16 mg)
37 Molecular and Cellular Characterization of Spongiotic Dermatitis Completed NCT00371163
38 Contact Allergens Causing Chronic Urticaria in a New England-Area Population Completed NCT00868036
39 Switching to Powder Free Latex Gloves in the Entire OR as Part of a New ' Latex Safe' Protocol: a Safe Alternative? A Prospective, Observational Cohort Study Completed NCT02575053
40 Cutaneous and Systemic Reactions to Metal Implants: Utility of Patch Testing Prior and Post Placement of Metal Orthopedic Implants Recruiting NCT02483728
41 Quality of Life Assessment Before and After Hyposensitization Treatment in Systemic Nickel Allergy Syndrome Recruiting NCT03731494
42 Improving Value of Care for Patients With Severe Stasis Dermatitis Recruiting NCT03022786
43 An Investigator Initiated Study to Evaluate the Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions In Healthy Adult Male Subjects Not yet recruiting NCT03945760 Early Phase 1 Baricitinib;Placebo
44 RESTenosis in Patients With Contact ALLergy to Metals Zabrze Study Not yet recruiting NCT03588962
45 Evaluation of the Therapeutic Effect and Local Tolerability of Elidel® Cream 1% (Pimecrolimus) in Chronic Discoid Lupus Erythematosus (dLE) or Subacute Cutaneous Lupus Erythematosus (scLE) Withdrawn NCT00222183 Elidel (pimecrolimus)

Search NIH Clinical Center for Allergic Contact Dermatitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Clobetasone
methdilazine
Methdilazine hydrochloride
Trimeprazine
trimeprazine tartrate

Cochrane evidence based reviews: dermatitis, allergic contact

Genetic Tests for Allergic Contact Dermatitis

Anatomical Context for Allergic Contact Dermatitis

MalaCards organs/tissues related to Allergic Contact Dermatitis:

41
Skin, Testes, T Cells, Lymph Node, Eye, Bone, Monocytes

Publications for Allergic Contact Dermatitis

Articles related to Allergic Contact Dermatitis:

(show top 50) (show all 6437)
# Title Authors PMID Year
1
Molecular diagnostics of psoriasis, atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis. 9 38
19818069 2010
2
Filaggrin mutations and allergic contact sensitization. 9 38
18478014 2008
3
Leukotriene B(4) enhances tumour necrosis factor-alpha-induced CCL27 production in human keratinocytes. 9 38
17581202 2007
4
Human arylamine N-acetyltransferase 2 polymorphism and susceptibility to allergic contact dermatitis. 9 38
16533241 2006
5
CCL22-induced responses are powerfully enhanced by synergy inducing chemokines via CCR4: evidence for the involvement of first beta-strand of chemokine. 9 38
15714581 2005
6
Th(1)/Th(2) responses to drugs. 9 38
11164989 2001
7
IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines. 9 38
10903743 2000
8
Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. 9 38
10886512 2000
9
The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. 9 38
10504443 1999
10
Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). 9 38
10233762 1999
11
IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. 9 38
9886425 1999
12
Interleukin-4 and the interleukin-4 receptor in allergic contact dermatitis. 9 38
9504244 1998
13
Pentoxifylline in vivo and in vitro down-regulates the expression of the intercellular adhesion molecule-1 in monocytes. 9 38
9155652 1997
14
4A11, a monoclonal antibody recognizing a novel antigen expressed on aberrant vascular endothelium. Upregulation in an in vivo model of contact dermatitis. 9 38
8311112 1994
15
Langerhans' cell expression of the selectin ligand, sialyl Lewis x. 9 38
7512530 1994
16
Effect of various metals on intercellular adhesion molecule-1 expression and tumour necrosis factor alpha production by normal human keratinocytes. 9 38
7864660 1994
17
[Immune mechanisms of atopic dermatitis]. 9 38
7507285 1993
18
Expression of adhesion molecules in early allergic patch test reactions. 9 38
1638065 1992
19
Keratinocyte expression of intercellular adhesion molecule 1 (ICAM-1) correlated with infiltration of lymphocyte function associated antigen 1 (LFA-1) positive cells in evolving allergic contact dermatitis reactions. 9 38
1682230 1991
20
Endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in cutaneous inflammation. 9 38
1706195 1991
21
[Allergic contact dermatitis from a new dentin adhesive system]. 9 38
2151486 1990
22
[Contact dermatitis, due to (di)methacrylates, on the hands of dental personnel]. 9 38
2144665 1990
23
Expression of intercellular adhesion molecule-1 in murine allergic contact dermatitis. 9 38
1983170 1990
24
Metal nanomaterials: Immune effects and implications of physicochemical properties on sensitization, elicitation, and exacerbation of allergic disease. 38
31195861 2019
25
The effects of para-phenylenediamine (PPD) on the skin fibroblast cells. 38
30474463 2019
26
Dermatology ECHO: A case presentation demonstrating benefits of specialty telementoring in primary care. 38
29933723 2019
27
Evaluation of in vitro testing strategies for hazard assessment of the skin sensitization potential of "real-life" mixtures: The case of henna-based hair-colouring products containing p-phenylenediamine. 38
31006869 2019
28
Adding sorbitan sesquioleate to the European baseline series: Necessary, reasonable, or unavoidable? 38
31177535 2019
29
Spinal IL-33/ST2 signaling mediates chronic itch in mice through the astrocytic JAK2-STAT3 cascade. 38
31087583 2019
30
Allergic contact dermatitis caused by oxidized linalool in a deodorant. 38
30912148 2019
31
Artificial nail wearing: Unexpected elicitor of allergic contact dermatitis, oral lichen planus and risky arthroplasty. 38
30793321 2019
32
Allergic contact dermatitis by isobornyl acrylate in glucose monitoring devices: Report of two cases. 38
31281970 2019
33
Allergic contact dermatitis caused by glucose sensors in type 1 diabetes patients. 38
31206704 2019
34
Allergic contact dermatitis caused by synthetic rubber gloves in healthcare workers: Sensitization to 1,3-diphenylguanidine is common. 38
30891769 2019
35
αEβ7 Expression Increases With the Extent of Cutaneous Involvement in Mycosis Fungoides. 38
30839339 2019
36
The epidemic of methylisothiazolinone contact allergy in Europe: follow-up on changing exposures. 38
31419348 2019
37
Etiological Contact Allergen Chemical Identification and Confirmation. 38
31433381 2019
38
Contact Allergy to and Other Adverse Effects of Fragrances: A Brief Overview. 38
31433384 2019
39
Contact allergen (PPD and DNCB)-induced keratinocyte sensitization is partly mediated through a low molecular weight hyaluronan (LMWHA)/TLR4/NF-κB signaling axis. 38
31226360 2019
40
Skin sensitizing effects of sulfur mustard and other alkylating agents in accordance to OECD guidelines. 38
31404593 2019
41
Acrylate allergic contact dermatitis by hair prosthesis fixative. 38
31423595 2019
42
Allergic contact dermatitis and electronic cigarettes: Is nickel to blame? 38
30834540 2019
43
Allergic contact dermatitis caused by neem oil: An underrated allergen? 38
30834541 2019
44
Allergic contact dermatitis caused by a Brazilian exotic hardwood. 38
30843225 2019
45
Highlights in allergic contact dermatitis 2018/2019. 38
31145193 2019
46
Occupational allergic contact dermatitis from systemic drugs. 38
31400016 2019
47
Allergic contact dermatitis caused by 1,6-hexanediol diacrylate in a hospital wristband. 38
31392731 2019
48
Allergic contact dermatitis following occupational exposure to various exotic and domestic woods. 38
31392734 2019
49
Do it Yourself Without Allergic Contact Dermatitis: Safe Household Cleaning Product Alternatives. 38
31433380 2019
50
Genipin in Temporary Jagua Tattoos-Another Black Dye Causing Severe Allergic Contact Dermatitis. 38
31433383 2019

Variations for Allergic Contact Dermatitis

Expression for Allergic Contact Dermatitis

Search GEO for disease gene expression data for Allergic Contact Dermatitis.

Pathways for Allergic Contact Dermatitis

Pathways related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 TNF IL5 IL4 IL33 IL31 IL1B
2
Show member pathways
13.88 TNF IL5 IL4 IL1B IL17A IL10
3
Show member pathways
13.72 TNF IL5 IL4 IL33 IL31 IL1B
4
Show member pathways
13.62 TNF IL5 IL4 IL1B IL17A IL10
5
Show member pathways
13.5 TNF IL5 IL4 IL1B IL17A IL10
6
Show member pathways
13.39 TNF IL5 IL4 IL1B IL17A IL10
7
Show member pathways
13.38 TNF IL5 IL4 IL33 IL31 IL1B
8
Show member pathways
13.08 TNF IL1B IL10 IFNG CXCL8
9
Show member pathways
12.98 TNF IL5 IL4 IL1B IL17A IL10
10
Show member pathways
12.8 TNF IL33 IL1B IFNG CXCL8
11
Show member pathways
12.73 TNF IL5 IL4 IL1B IL17A IL10
12
Show member pathways
12.69 TNF IL1B IL17A IL10 IFNG CD4
13
Show member pathways
12.69 TNF IL5 IL4 IL1B IL17A IL10
14
Show member pathways
12.68 TNF IL4 IL10 IFNG CD4
15 12.66 TNF IL4 IL1B IL17A IL10 IFNG
16
Show member pathways
12.52 TNF IL4 IFNG ICAM1
17
Show member pathways
12.43 TNF IL4 IL1B IFNG ICAM1
18
Show member pathways
12.41 IL5 IL4 IL10 IFNG
19
Show member pathways
12.41 TNF IL5 IL4 IL1B IL17A IFNG
20
Show member pathways
12.4 TNF IL5 IL4 IL1B IL17A IL10
21
Show member pathways
12.36 TNF IL4 IL1B IL10 IFNG
22
Show member pathways
12.34 TNF IL1B IFNG CXCL8
23 12.29 TNF IL1B IL10 IFNG
24
Show member pathways
12.29 TNF IL4 IL1B IFNG CXCL8
25
Show member pathways
12.28 TNF IL33 IL1B CXCL8
26
Show member pathways
12.27 TNF IL33 IL1B IFNG
27
Show member pathways
12.26 CXCR3 CXCL8 CCL17
28
Show member pathways
12.26 TNF IL1B IL10 CCL17
29
Show member pathways
12.24 IL1B ICAM1 CXCR3 CXCL8 CCL17
30 12.23 TNF IL1B IL10 CXCL8
31 12.21 TNF SELE IL1B IFNG ICAM1
32
Show member pathways
12.21 TNF IL1B IL17A IL10 IFNG CD4
33 12.17 TNF IL4 IL1B IFNG ICAM1 CXCL8
34 12.15 TNF IL5 IL4 IL10 IFNG CD4
35
Show member pathways
12.11 TNF IL4 IL1B IFNG
36 12.11 TNF IL4 IL1B IL17A IL10 ICAM1
37
Show member pathways
12.08 IL5 IL4 IL1B IL17A IL10 IFNG
38 12.07 TNF IL1B IL10 IFNG CXCL8
39
Show member pathways
12.06 IL4 IL1B IFNG CD4
40 12.06 TNF SELE IL1B ICAM1 CXCL8
41 12.05 TNF SELE IL1B ICAM1
42 12.05 TNF IL5 IL4 IL1B CD4
43 12.04 TNF IL1B IL17A IFNG ICAM1 CXCL8
44 12.01 TNF IL1B ICAM1 CXCL8
45 11.97 SELE IL5 IL4 IFNG ICAM1 CXCL8
46 11.95 IL1B IFNG CXCL8
47
Show member pathways
11.93 TNF IL5 IL4 IFNG CXCL8
48 11.91 TNF IL1B IL10 IFNG CD4
49
Show member pathways
11.89 IL17A ICAM1 CXCL8
50 11.87 TNF IL1B IL10 CXCL8

GO Terms for Allergic Contact Dermatitis

Cellular components related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 TNF IL5 IL4 IL33 IL31 IL1B
2 membrane raft GO:0045121 9.56 TNF SELE ICAM1 CD4
3 external side of plasma membrane GO:0009897 9.55 TNF IL17A ICAM1 CXCR3 CD4
4 extracellular space GO:0005615 9.44 TNF SELE IL5 IL4 IL33 IL31

Biological processes related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.94 TNF SELE IL1B ICAM1
2 positive regulation of protein phosphorylation GO:0001934 9.92 TNF IL1B IFNG CD4
3 response to lipopolysaccharide GO:0032496 9.91 SELE IL1B IL10 ICAM1
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.87 IL5 ICAM1 CD4
5 calcium-mediated signaling GO:0019722 9.86 SELE CXCR3 CXCL8
6 neutrophil chemotaxis GO:0030593 9.86 IL1B CXCL8 CCL17
7 chemokine-mediated signaling pathway GO:0070098 9.85 CXCR3 CXCL8 CCL17
8 regulation of insulin secretion GO:0050796 9.84 TNF IL1B IFNG
9 positive regulation of T cell proliferation GO:0042102 9.83 IL4 IL1B CD4
10 positive regulation of interleukin-6 production GO:0032755 9.83 TNF IL33 IL1B
11 positive regulation of DNA-binding transcription factor activity GO:0051091 9.83 TNF IL5 IL1B IL10
12 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.81 TNF ICAM1 CD4 CCL17
13 inflammatory response GO:0006954 9.81 TNF SELE IL5 IL1B IL17A IL10
14 cellular response to lipopolysaccharide GO:0071222 9.8 TNF IL1B IL10 ICAM1 CXCL8
15 extrinsic apoptotic signaling pathway GO:0097191 9.78 TNF IL33 IFNG
16 cellular response to interleukin-1 GO:0071347 9.78 IL17A ICAM1 CXCL8 CCL17
17 negative regulation of endothelial cell apoptotic process GO:2000352 9.73 IL4 IL10 ICAM1
18 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.72 TNF IL1B
19 positive regulation of macrophage activation GO:0043032 9.71 IL33 IL10
20 positive regulation of glial cell proliferation GO:0060252 9.71 TNF IL1B
21 negative regulation of lipid catabolic process GO:0050995 9.71 TNF IL1B
22 negative regulation of growth of symbiont in host GO:0044130 9.71 TNF IL10
23 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.7 IL1B CD4
24 response to molecule of bacterial origin GO:0002237 9.7 IL10 CXCL8
25 positive regulation of podosome assembly GO:0071803 9.7 TNF IL5
26 positive regulation of immunoglobulin secretion GO:0051024 9.7 IL5 IL33
27 immune response GO:0006955 9.7 TNF IL5 IL4 IL1B IL17A IL10
28 positive regulation of chemokine secretion GO:0090197 9.69 TNF IL33
29 positive regulation of interleukin-13 production GO:0032736 9.68 IL4 IL33
30 positive regulation of chemokine biosynthetic process GO:0045080 9.68 TNF IL1B
31 endothelial cell apoptotic process GO:0072577 9.67 TNF IL10
32 response to glucocorticoid GO:0051384 9.67 TNF IL10
33 positive regulation of osteoclast differentiation GO:0045672 9.67 TNF IL17A IFNG
34 positive regulation of nitric oxide biosynthetic process GO:0045429 9.67 TNF IL1B IFNG ICAM1
35 regulation of establishment of endothelial barrier GO:1903140 9.66 TNF IL1B
36 positive regulation of MHC class II biosynthetic process GO:0045348 9.66 IL4 IL10
37 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.65 TNF ICAM1
38 negative regulation of cytokine secretion involved in immune response GO:0002740 9.64 TNF IL10
39 positive regulation of interleukin-23 production GO:0032747 9.63 IL17A IFNG
40 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.63 TNF IL1B IFNG
41 positive regulation of fever generation GO:0031622 9.62 TNF IL1B
42 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.61 TNF IL1B IL10
43 type 2 immune response GO:0042092 9.6 IL4 IL10
44 sequestering of triglyceride GO:0030730 9.59 TNF IL1B
45 regulation of isotype switching GO:0045191 9.58 IL4 IL10
46 receptor biosynthetic process GO:0032800 9.57 TNF IL10
47 positive regulation of vitamin D biosynthetic process GO:0060557 9.54 TNF IFNG
48 positive regulation of neuroinflammatory response GO:0150078 9.5 TNF IL33 IL1B
49 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.43 TNF IL1B IFNG
50 cytokine-mediated signaling pathway GO:0019221 9.32 TNF IL5 IL4 IL31 IL1B IL17A

Molecular functions related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.8 TNF SELE IL5 IL4 IL33 IL1B
2 cytokine activity GO:0005125 9.36 TNF IL5 IL4 IL33 IL31 IL1B

Sources for Allergic Contact Dermatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....